I-cell disease or mucolipidosis type II, a rare inherited storage disorder of lysosomal enzyme localization, is characterized by dysostosis multiplex, progressive severe psychomotor retardation and death by 5-8 years from congestive heart failure and recurrent pulmonary infections. A 19-month old girl with I-cell disease received a bone marrow transplant (BMT) from an HLA-identical carrier brother. At the age of 7 years, 5 years after BMT, she has no history of respiratory infections. Her cardiac function remains normal with a shortening fraction of 47%, and she continues to gain neurodevelopmental milestones, albeit at a very slow rate. Musculoskeletal deformities have worsened despite BMT. This is the first report describing neurodevelopmental gains and prevention of cardiopulmonary complications in I-cell disease after BMT. Bone Marrow Transplantation (2003) 32, 957-960. doi:10.1038/sj.bmt.1704249 Keywords: hematopoietic cell transplantation; I-cell disease; mucolipidosis II I-cell disease or mucolipidosis II (ML-II) is a rare autosomal recessive disorder resulting from defective intracellular trafficking of lysosomal enzymes in cells of mesenchymal origin. 1, 2 Clinical features resemble Hurler's syndrome with facial dysmorphology, hepatosplenomegaly, progressive cardiac dilatation and dysfunction, hernias, neurocognitive delay, and multiple skeletal deformities (dysostosis multiplex).
1,3 ML-II patients can be differentiated clinically from Hurler's syndrome by an earlier age of onset, prominent gingival hypertrophy, severe psychomotor (particularly motor) retardation, and absence of mucopolysacchariduria.
Physiologically, enzymes normally destined for the lysosomes undergo phosphorylation on position 6 of a mannose residue in a two-step process inside the Golgi apparatus, to synthesize a mannose 6-phosphate recognition marker which allows targeting of the enzyme to the lysosomes. 4 In ML-II, the enzyme GlcNAc phosphotransferase (or phosphotransferase), catalyzing the first-step of phosphorylation, is defective. 2 This results in deficient synthesis of the recognition marker on enzymes destined for the lysosomes and instead leakage of lysosomal enzymes into body fluids and serum. Patients have severe and progressive mental retardation with recurrent respiratory infections; death usually occurs by 5-8 years of age due to cardiorespiratory complications. Diagnosis can be established by clinical features and biochemically by demonstrating deficiency of the phosphotransferase in leukocytes/ tissues or significantly increased levels of lysosomal enzymes in serum.
Hickman and Neufeld, in 1972, 5 showed that I-cell fibroblasts were capable of internalizing lysosomal enzymes secreted by normal cells, but normal cells were unable to take up enzymes secreted by I-cell fibroblasts. This formed our basis for considering allogeneic bone marrow transplantation (BMT). This is the first report describing continued intellectual development with prevention of cardiorespiratory complications in a patient with ML-II after BMT.
Case report
A 12-month-old girl was evaluated in the genetics clinic for progressive facial dysmorphia since birth. There was no prior history of respiratory infections. Physical features included gingival hypertrophy, diastasis rectii, hepatomegaly (5 cm below the costal margin), no cardiac murmurs, and prominent kyphosis. Skeletal survey showed classical radiological features of dysostosis multiplex similar to that seen in Hurler's syndrome. She was unable to sit or crawl, but had good head control and reached for objects. Leukocyte alpha-l-iduronidase enzyme activity was normal and no mucopolysacchariduria was detected. Further evaluation revealed a low leukocyte GlcNAc phosphotransferase activity (6.5% of control) with increased plasma activity of multiple lysosomal enzymes (b-galactosidase, 490% of control; a-mannosidase, 2980% of control).
She was referred to the Pediatric Blood and Marrow Transplantation division for consideration of BMT. At 19 months, she underwent BMT from her 5-year-old brother who was HLA-identical, with a leukocyte phosphotransferase enzyme level in the carrier range. At that time, she had a three-word monosyllable vocabulary, could stand with support and crawl. Neuropsychological assessment before transplant is shown in Table 1 .
Methods
Enzyme activity determinations were performed by Yoav Ben-Yoseph PhD (Biochemical and Molecular Genetics Laboratory, Wayne State University School of Medicine, Detroit, MI, USA), and reported as a percentage of an average of two control samples. The BMT preparative regimen was part of an IRB-approved protocol at the University of Minnesota and consisted of cyclophosphamide 60 mg/kg i.v. once daily on days 1 and 2 (total 120 mg/ kg), equine antithymocyte globulin (ATGAM, Upjohn Corporation) 30 mg/kg/day in two divided doses on days 4, 5, and 6 (total dose 90 mg/kg), and fractionated total body irradiation 200 cGy twice daily on days 4, 5, and 6, and a single dose on day 7 (total dose 1400 cGy). The donor marrow was T-cell depleted by elutriation. 6 The nucleated cell dose of the infused marrow was 1.3 Â 10 8 /kg. Graftversus-host disease (GVHD) prophylaxis was provided with cyclosporin A and prednisone. Donor chimerism was determined by semiquantitative restriction fragment length polymorphism analysis of peripheral blood-derived leukocytes. A battery of standardized neuropsychological tests was used to assess the developmental and intellectual level and adaptive behavior. The specific test used changed with the age of the patient (Table 1) .
Results

Engraftment
The time to myeloid engraftment (absolute neutrophil count 40.5 Â 10 9 /l) and untransfused platelet count 450 Â 10 9 /l was 12 and 73 days, respectively. Peripheral blood donor chimerism was evaluated at days 21, 60, 100, 180 and yearly thereafter, and was 100% donor at all time points. The donor's leukocyte phosphotransferase enzyme activity prior to marrow harvest was 68% of control (in heterozygous carrier range). The patient's leukocyte phosphotransferase enzyme activity before transplant was 6.5% of control. Measurements at days 60, 100, and 180 after BMT detected levels at 20-24% of the control value. Recent testing showed levels of plasma lysosomal enzymes (including a-mannosidase and b-galactosidase) to be 5-10 times elevated over normal controls.
Transplant-related complications
Grade II acute gastrointestinal GVHD developed. It was effectively treated by 2 mg/kg/day of oral prednisone, which was tapered over 9 weeks. At 8 months after BMT, multiple liver nodules were detected on CT scan. A biopsy revealed EBV-positive B-cell lymphoma, which was successfully treated by withdrawal of immunosuppresion and one donor lymphocyte infusion (2 Â 10 6 mononuclear cells/kg).
Cardiorespiratory and gastrointestinal status
The patient had trivial aortic insufficiency with a slight thickening of the mitral valve prior to transplantation. The shortening fraction was 45% and no cardiomegaly was observed. Yearly Doppler and two-dimensional echocardiographic evaluations after transplant demonstrated no significant change in cardiac function. Five years after BMT, she has mild mitral regurgitation, trivial aortic insufficiency, no cardiomegaly, and a shortening fraction of 47%. There have been no documented respiratory infections or complications after BMT. The hepatomegaly resolved by 4 months after transplant, the gingival hypertrophy has partially regressed and diastasis rectii persists.
Neurocognitive status
Serial neuropsychological tests were performed beginning before transplant and yearly thereafter (Table 1 and Figure 1 ). The patient has made slow progress in all domains including adaptive skills such as communication, daily living, and socialization skills. Her gross motor development and receptive language are most impaired, while her visual skills, fine motor skills, and expressive BMT for I-cell disease language are relatively stronger and showing continued but slow growth.
No gained developmental milestones have been lost. No significant behavioral problems have been reported or observed with the exception of tantrums, which became less frequent and have resolved with time. At the last follow-up, progress was noticed primarily in receptive language, behavior, and cooperation over the previous evaluation 1 year ago. At age 7 years, she is a first grade student in elementary school and follows an individual education program. She is classified as mild to moderately cognitively impaired. She can speak three-word sentences, can walk without difficulty, and follows directions.
Other aspects
Thyroid function assays and growth hormone levels (last checked at age 6.5 years) were in the normal range. She has developed progressive genu valgum, bilateral hip dysplasia, and kyphosis, which are anticipated to need future surgery. To date, she has required surgeries for left cataract extraction with intra-ocular lens placement (age 4 years), bilateral carpal tunnel and eight trigger digit releases (age 6 years), and multiple dental extractions and restorations (age 6 years). Bilateral pressure equalizing ear tubes were inserted (age 3 years) after flat tympanograms were observed. Subsequent yearly audiograms have revealed no hearing deficits.
Discussion
Patients with ML-II have severe and progressive mental and motor retardation. Death typically results by 5-8 years from progressive cardiac failure and/or recurrent pulmonary symptoms. In a previous report, an 8-month-old Japanese girl with ML-II received an HLA-identical BMT from a heterozygote brother. 7 At transplant, a history of recurrent apneic episodes and progressive cardiac dysfunction was present. Biochemical correction was noted after transplant. In a follow-up report, 8 no further progression of cardiac dysfunction was noted, and she maintained developmental skills of a 4-8-month old until her death from recurrent respiratory infections 5.5 years after transplant.
Our patient, who is over 7 years of age, is surviving without any evidence of the usual etiologies leading to death: progressive cardiac disease or recurrent respiratory infections. The mild cardiac valvular disease (mitral valve thickening and trace aortic insufficiency) has not regressed after transplant, but neither has it progressed, as would be expected with the natural history of the disease.
Neurodevelopmentally, contrary to the course in untreated patients, a trajectory of increasing achievement of milestones has been observed, albeit at a very slow rate. At age 6.8 years, she functioned at a level close to a 3-year-old in several domains, but progress was particularly lacking in gross motor and receptive language domains. Of note, no gained milestones were lost at any point. Interestingly, this profile is quite similar to that of children with severe Hurler's syndrome who gain developmentally but at a slower rate. 9, 10 This documents that successful BMT can permit continued neurocognitive progress, albeit with limitations. It is difficult to predict the trajectory and scope of future progress.
There is no evidence that the BMT altered the course of musculoskeletal disease. This course is similar to the much larger experience in a phenotypically similar disorder, Hurler's syndrome, where transplant can provide benefits for cardiac and neurological disease, but does not benefit musculoskeletal disease. It would appear that chondroblasts and osteoblasts are relatively insulated from the beneficial effects of BMT.
The exact mechanism of benefit after BMT is unclear. While clinically the neurocognitive course and cardiopulmonary status were favorably altered, the plasma lysosomal enzymes remained elevated after BMT. There was a partial improvement in the leukocyte phosphotransferase level. The incomplete phosphotransferase correction was related to the carrier status of the donor and possibly other undefined factor(s). It is possible that low levels of phosphotransferase enzyme activity are sufficient for clinical improvement; however, further experience will elucidate if higher achieved phosphotransferase enzyme activity levels in the recipient (eg from a homozygous normal donor) can provide superior benefit.
In summary, in this patient with ML-II, allogeneic BMT has prevented progressive cardiac and pulmonary disease, allowed continued achievement of neurodevelopmental skills, although at a slower than normal rate, and may potentially lead to long-term survival. It is possible that significant benefits may be achieved only if patients are transplanted early in the course of the disease. 
